Evidence map›Paper›PMID 39879245›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Serine phosphorylation facilitates protein degradation by the human mitochondrial ClpXP protease.

Yue Feng, Monica M Goncalves, Yulia Jitkova, Alexander F A Keszei, Yongran Yan, Chaitra Sarathy, Jonathan St-Germain, Tristan M G Kenney, Matthew Tcheng, Vincent Trudel and 18 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Molecular mechanisms of mitochondrial AAA+ proteases.The Journal of biological chemistry · 2026
    Review
  5. Article
  6. Review
  7. Mitochondrial Protease ClpP: Cancer Marker and Drug Target.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Yue FengPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0009-0002-9697-1903
Monica M GoncalvesDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Yulia JitkovaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Alexander F A KeszeiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Yongran YanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0009-0005-7337-4331
Chaitra SarathyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0000-0003-1115-4323
Jonathan St-GermainPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Tristan M G KenneyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0000-0001-8242-4349
Matthew TchengPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Vincent TrudelDepartment of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada.
Ross S ManciniKrembil Brain Institute, University Health Network, Toronto, ON M5T 1M8, Canada.
Rahul UpadhyayKrembil Brain Institute, University Health Network, Toronto, ON M5T 1M8, Canada.
Rose HurrenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Marcela GrondaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Matthew SchultzPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Kaylen SorianoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Kaitlin LeesPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Neil C PomroyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0009-0009-1921-1709
S Quinn W CurrieDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Gilbert G PrivéPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Mark A ReedDepartment of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada.
Andrei K YudinDepartment of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada.
Linda Z PennPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0000-0001-8133-5459
Cheryl H ArrowsmithPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Brian RaughtPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Mohammad T Mazhab-JafariPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0000-0003-0207-5877
Siavash Vahidi *Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0001-8637-3710
Aaron D Schimmer *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.

Funding

Canadian Government | Canadian Institutes of Health Research (CIHR) PJT-186334Canadian Government | Canadian Institutes of Health Research (CIHR) PJT-191940Cancer Research Society (CRS) 127241
6 · The paper itself

Abstract

ClpXP is a two-component mitochondrial matrix protease. The caseinolytic mitochondrial matrix peptidase chaperone subunit X (ClpX) recognizes and translocates protein substrates into the degradation chamber of the caseinolytic protease P (ClpP) for proteolysis. ClpXP degrades damaged respiratory chain proteins and is necessary for cancer cell survival. Despite the critical role of ClpXP in mitochondrial protein quality control, the specific degrons, or modifications that tag substrate proteins for degradation by human ClpXP, are still unknown. We demonstrated that phosphorylated serine (pSer) targets substrates to ClpX and facilitates their degradation by ClpXP in biochemical assays. In contrast, ClpP hyperactivated by the small-molecule drug ONC201 lost the preference for phosphorylated substrates. Hydrogen deuterium exchange mass spectrometry combined with biochemical assays showed that pSer binds the RKL loop of ClpX. ClpX variants with substitutions in the RKL loop failed to recognize phosphorylated substrates. In intact cells, ClpXP also preferentially degraded substrates with pSer. Moreover, ClpX substrates with the pSer were selectively found in aggregated mitochondrial proteins. Our work uncovers a mechanism for substrate recognition by ClpXP, with implications for targeting acute myeloid leukemia and other disorders involving ClpXP dysfunction.

Indexed as

Endopeptidase ClpMitochondriaMitochondrial ProteinsSerineHumansMolecular ChaperonesPhosphorylationProteolysisSubstrate SpecificityClpP protein, humanCLPX protein, humanEndopeptidase ClpMitochondrial ProteinsMolecular ChaperonesSerineAAA+ proteasesdegronmitochondrial proteostasisphosphorylationprotein degradation

Identifiers

PMID39879245
PMCPMC11804671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.